Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million - Seite 2
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel,
Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with
leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the
world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
Novartis Media Relations
Central media line: +41 61 324 2200 | |
Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com |
Elizabeth Power Novartis Global Media Relations +1 212 830 2466 +1 617 583 3015 elizabeth.power@novartis.com |
e-mail: media.relations@novartis.com
For Novartis multimedia content, please visit: www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.
Novartis Investor Relations
Central phone: | +41 61 324 7944 | ||
Samir Shah | +41 61 324 7944 | North America: | |
Pierre-Michel Bringer | +41 61 324 1065 | Richard Pulik | +1 212 830 2448 |
Thomas Hungerbuehler | +41 61 324 8425 | Sloan Pavsner | +1 212 830 2417 |
Isabella Zinck | +41 61 324 7188 | ||
e-mail: investor.relations@novartis.com | e-mail: investor.relations@novartis.com |
Lesen Sie auch